U.S. sales medical device sales dropped 5.6 percent in the second quarter to $3 billion during the quarter.
Five things to know about Johnson & Johnson’s orthopedics sales:
1. Overall, second quarter orthopedics sales dropped 1.6 percent to $2.2 billion. U.S. sales were flat at $1.3 billion and international sales dropped 3.8 percent to $894 million. Worldwide orthopedic sales at the six months end dropped 2 percent to $4.4 billion.
2. Worldwide hip sales were up 0.9 percent to $364 million. U.S. hip sales jumped 2.1 percent to $216 million while international sales dropped slightly to $147 million.
3. U.S. knee sales decreased 4.8 percent to $218 million while international knee sales were flat at $153 million. Worldwide knee sales were down 2.8 percent to $372 million.
4. The international spine and other segment sales dipped 5.3 percent in the second quarter to $328 million, while U.S. spine sales dropped 1.5 percent to $490 million. Worldwide, the company reported a 3.1 percent drop in spine sales to $818 million.
5. Orthopedic trauma sales dipped 0.6 percent to $672 million worldwide. U.S. orthopedic trauma sales increased 3.3 percent to $407 million while international sales declined 5.9 percent to $265 million.
More articles on orthopedic devices:
34 orthopedic, spine devices receive FDA 510(k) clearance in June
Medtronic, Smith & Nephew & more: 10 device company notes
Medtronic secures market position through Titan Spine acquisition, analyst says
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
